QT VASCULAR LTD.
(Company Registration No. 201305911K)
(Incorporated in the Republic of Singapore)

RESULTS OF SCHEME MEETING

---

1. INTRODUCTION

The Board of Directors ("**Board**") of QT Vascular Ltd. ("**Company**") refers to the following:

(a) the previous announcements on 2 March 2022, 22 March 2022, 11 May 2022, 19 May 2022 and 1 June 2022 ("**Previous Announcements**") in relation to, *inter alia*, the proposed restructuring of the Company to Quantum Healthcare Limited, the Proposed Options Variation and Proposed Awards Variation, by way of a scheme of arrangement under Section 210 of the Companies Act 1967 ("**Scheme**"); and

(b) the scheme document to Shareholders dated 1 June 2022 ("**Scheme Document**").

Unless otherwise defined, all capitalised terms used and not defined herein shall have the same meanings given to them in the Previous Announcements and the Scheme Document.

2. RESULTS OF SCHEME MEETING

2.1 The Board is pleased to announce that the Scheme Resolution as set out in the Notice of the Scheme Meeting dated 1 June 2022 were duly approved and passed at the Scheme Meeting today by a majority in number of Shareholders, representing not less than three-fourths in value of the Shares held by the Shareholders, present and voting, either in real time or by proxy.

2.2 The poll results on the Scheme Resolution put to vote at the Scheme Meeting is as follows:

Resolution		**FOR**		**AGAINST**		**Total**
		Number	Percentage (%)	Number	Percentage (%)	
To approve the Scheme of Arrangement	Shareholders present and voting (either in person or by proxy)	18	100	0	0	18
	Shares represented by votes (either in person or by proxy)	4,476,838,348	100	0	0	4,476,838,348

3. ABSTENTIONS FROM VOTING

As set out in the Scheme Document, shareholders who hold Options under any Option Schemes and Awards under the QT Vascular Restricted Share Plan 2015 have abstained from voting at the Scheme Meeting in respect of the Scheme Resolution.

4. SCRUTINEER

Kreston David Yeung PAC was appointed scrutineer for the Scheme Meeting.

5. NEXT STEPS AND INDICATIVE TIMETABLE FOR THE SCHEME

The Company will be making an application to the Court to sanction the Scheme under Section 210 of the Companies Act which shall become effective if all the Conditions Precedent have been satisfied or waived (as the case may be) and binding upon the lodgment of the Court Order with ACRA.

As set out in the Scheme Document, Shareholders should note the following indicative timetable in relation to the Scheme:

Expected date of Court hearing of the application to sanction the Scheme	:	14 July 2022[(1)]
Expected Notice of Record Date	:	14 July 2022
Expected last day of trading of the Shares	:	20 July 2022
Expected Record Date	:	22 July 2022
Expected Effective Date	:	To be announced in due course by the Company, expected to be 25 July 2022
Expected date of debiting of Shares from the Securities Accounts of Depositors	:	28 July 2022
Expected date for the crediting of Shares to Quantum Healthcare	:	28 July 2022
Expected date for the crediting of Quantum Healthcare Shares into Securities Accounts of Depositors pursuant to the Scheme	:	28 July 2022
Expected date and time for the commencement of trading of Quantum Healthcare Shares on the SGX-ST	:	29 July 2022 at 9.00 a.m.
Expected date for the withdrawal of the Shares/delisting of the Company from the SGX-ST	:	29 July 2022

(1) The date of the Court hearing of the application to sanction the Scheme will depend on the date that is allocated by the Court.

The above dates are indicative only and may be subject to change. Please refer to future announcement(s) by the Company for the exact dates of these events.

6. DIRECTORS RESPONSIBILITLY STATEMENT

The Directors collectively and individually accept full responsibility for the accuracy of the information given in this announcement and confirm, after making all reasonable enquiries, that to the best of their knowledge and belief, this announcement constitutes full and true disclosure of all material facts about the Scheme as set out herein, the Company and its subsidiaries, and the Directors are not aware of any facts the omission of which would make any statement in this announcement misleading.

Where information in this announcement has been extracted from published or otherwise publicly available sources or obtained from a named source, the sole responsibility of the Directors has been to ensure that such information has been accurately and correctly extracted from those sources and/or reproduced in this announcement in its proper form and context.

BY ORDER OF THE BOARD

Thomas Tan Gim Chua
Chief Executive Officer
24 June 2022

*This announcement has been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. ("**Sponsor**"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited ("**Exchange**") and the Exchange assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.*

The contact person for the Sponsor is Ms Lim Hui Ling, 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318, sponsorship@ppcf.com.sg.